SAMe with Vitamins B-6 B-12 and 5-MTHF

SAMe with Vitamins B-6 B-12 and 5-MTHF

Designs for Health5.0 (11 ratings)
Format:Capsule Quantity: 30 Capsule(s) · 30 servings
Goals
$60.49 $2.01 per serving
Pure Formulas$60.49

About this product

The formula combines SAMe with P-5-P vitamin B6, methylfolate, and methylcobalamin. Those companion nutrients fit the product's methylation and detoxification focus.

The disulfate p-toluenesulfate form supports chemical stability, but the label does not clarify net SAMe yield from the salt complex. A standard capsule without stated enteric protection may expose SAMe to stomach acid.

The amount suits cautious starting use rather than a full-strength serving. High cost and uncertain delivery are the main practical drawbacks.

Who is it for
  • Adults seeking low-dose SAMe with methylated B vitamins
  • Users beginning a SAMe routine cautiously
  • People focused on methylation support
Best for
  • Starting-dose SAMe
  • Combined methylation nutrients
  • Detoxification-oriented supplementation

Pros

  • Stable SAMe salt is named
  • Includes P-5-P vitamin B6
  • Uses methylfolate and methylcobalamin
  • All active amounts are disclosed

Cons

  • No stated enteric protection
  • Net active SAMe yield is unclear
  • High cost for the serving
  • No sealed blister packaging identified

Warnings

  • SAMe may provoke mania in people with bipolar disorder
  • Do not combine with SSRIs, SNRIs, MAO inhibitors, triptans, or other serotonergic agents without medical oversight
  • SAMe may cause nausea, anxiety, or insomnia, particularly when taken later in the day

Product analysis

66 out of 100
Thoughtful methylated B-vitamin support accompanies a stable SAMe salt, but delivery protection, active yield, and value are weak.

AI assessment of the formula, label and price. How scoring works

Nutrient quality83

A stabilized salt supports shelf stability, but no acid-resistant delivery is stated. A common starting amount is practical, although net SAMe yield remains unclear.

Ingredient transparency72

Most active quantities are stated without a hidden blend. Repeated entries, unclear net SAMe yield, missing directions, and absent excipients reduce transparency.

Customer satisfaction59

The supplied average rating is very strong and the rating volume is limited. No specific experience details were provided to judge repeated complaints or purpose alignment.

Value for money46

Delivery limitations or high cost weaken practical value. Better-protected or more efficiently priced alternatives are more competitive.

Format
Capsule
Container
30 Capsule(s)
Per serving
$2.01
Customer rating
5.0 · 11 ratings
Report analysis

Goals

Detoxification
Detoxification
Impact
High effect
B- Ingredient FitD PathwaysB+ EvidenceA+ Formulation Logic
Folate · 100 mcgVitamin B12 · 50 mcgVitamin B6 · 5 mgSAMe · 200 mg

SAMe participates in methyl-group supply, a normal chemical process in the body, but whether taking it improves routine toxin removal is unclear. Vitamin B12 and B6 also have related coenzyme roles. Those biological connections do not show that this combination clears alcohol or other unspecified toxins more quickly.

How this product is rated for Detoxification

Ingredient fit74

SAMe, B12 and B6 relate to methyl-group supply; that does not demonstrate routine toxin removal.
Goal fit
SAMe, B12 and B6 relate to methyl-group supply; that does not demonstrate routine toxin removal.
Dose adequacy
SAMe is 200 mg per serving, matching the lower comparison amount; this does not demonstrate routine toxin-clearance benefit.

Pathways46

The ingredients relate mainly to methyl-group supply, a normal biochemical process rather than a demonstrated general cleanse.
Depth
The ingredients relate mainly to methyl-group supply, a normal biochemical process rather than a demonstrated general cleanse.
Breadth
The connection centers on methyl-group supply rather than several distinct demonstrated toxin-removal effects.

Evidence85

Disease-specific SAMe effects cannot be assumed to apply to routine toxin removal; B-vitamin coenzyme roles do not resolve that uncertainty.
Evidence strength
Disease-specific SAMe effects cannot be assumed to apply to routine toxin removal; B-vitamin coenzyme roles do not resolve that uncertainty.
Studied preparation
The declared SAMe and B vitamins do not establish routine toxin-removal benefit from this preparation.

Formulation logic100

No particular ingredient conflict or missing required companion is identified. The combination does not by itself demonstrate an additional toxin-removal benefit.
Partner coverage
No required companion is missing for the relevant ingredients; this does not imply an additional combined benefit.
Conflicts
No particular ingredient conflict is identified for the declared serving.
Effective doses
SAMe is 200 mg per serving, matching the lower comparison amount; this does not demonstrate routine toxin-clearance benefit.
Study evidence
Folate Supportive 16 studies
SAMe Supportive 30 studies

Ingredients

IngredientAmount per servingScore
Vitamin B-6 (Pyridoxal 5-Phosphate)
 5 mg
Folate ([6s]-5-Methyltetrahydrofolate, Glucosamine Salt)
 100 mcg
Vitamin B12 (Methylcobalamin)
 50 mcg
SAMe (S-Adenosyl-L-Methionine Disulfate P-Toluensulfate)
 200 mg 35
Gluten Free Adults 18–50
Report overview
SAMe (S-Adenosyl-L-Methionine Disulfate P-Toluensulfate) · 200 mg OverallScore35
F Active Ingredient Quality & BioavailabilityC Dose, Safety & Label TransparencyF Value
The label lists 200 mg of SAMe per serving, a common starting amount in the supplied context. It does not identify a stabilizing salt or distinguish salt weight from net active SAMe. No blister or release claim is recorded, and the cost is high relative to the listed amount.
How this ingredient is rated

Active Ingredient Quality & Bioavailability17

The saved facts do not identify a stabilizing salt or individual blister packaging.
Stabilized Salt Form
The saved facts do not specify a stabilizing salt form for the SAMe.
Packaging Integrity
No individual blister-pack claim is recorded, so the packaging type remains unclear.

Dose, Safety & Label Transparency60

The label gives a SAMe amount, but does not distinguish salt weight from net active SAMe.
Active Dosage Strength
The label lists 200 mg of SAMe per serving, the common starting amount described in the supplied context.
Net SAMe Yield Transparency
Only one SAMe amount is listed, so salt-complex weight and net active SAMe are not distinguished.

Value20

The cost is high relative to the listed SAMe amount.
Price Per 400mg Active Dose
The normalized cost is high compared with the collection reference, and no enteric or delayed-release claim is recorded.
View ingredientView products
Loading alternative details
85 Performance

SAMe 400 mg

Lake Avenue Nutrition

A stabilized salt and enteric coating protect a full SAMe amount during storage and passage through the stomach. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Net active yield and moisture-resistant packaging remain unclear.

84 Performance

SAMe 400 mg

Life Extension

Enteric coating protects a full SAMe amount from stomach acid and supports purposeful delivery. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. The stabilized salt, net active yield, and moisture protection are not identified.

84 Performance

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt supplies a full SAMe amount in one tablet. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Enteric and sealed moisture protection are not stated, and net active yield remains unclear.

74 Budget

SAMe 200

Jarrow Formulas

A common starting SAMe amount provides a simple, low-cost option. It lowers routine cost versus the original. Neither a stabilized salt nor acid-resistant delivery is identified, so protected active yield is uncertain.

83 Budget

SAMe 200 mg

NOW

A stabilized disulfate tosylate salt provides a credible common starting amount at efficient routine value. It lowers routine cost versus the original. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

84 Budget

SAMe 400 mg

Nutricost

A stabilized salt provides a full SAMe amount with efficient dose value. It lowers routine cost versus the original. The two-capsule serving has no stated acid resistance, and moisture protection is unclear.

84 Value

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt provides a full SAMe amount with favorable dose value. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection and sealed moisture protection are not stated.

80 Value

SAMe 400 mg

Swanson

A stable disulfate tosylate form provides a full SAMe amount in one tablet. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

78 Value

SAMe 200 mg S-Adenosyl-Methionine

Life Extension

Enteric coating protects a common starting SAMe amount from stomach acid. Compared with the original, its delivery design and routine economics offer a useful value trade-off. The salt form, net active yield, and moisture protection are not identified.

Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
    Guo T; Chang L; Xiao Y; Liu Q · PloS one · 2015
    Meta-analysis705 participants11 studies pooledDetoxification forSAMe
  2. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial.
    Medici V; Virata MC; Peerson JM; Stabler SP; French SW; Gregory JF; Albanese A; Bowlus CL; Devaraj S; Panacek EA; Richards JR; Halsted CH · Alcoholism, clinical and experimental research · 2012
    Randomized trial37 participantsDetoxification forSAMe
  3. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
    Noureddin M; Sander-Struckmeier S; Mato JM · World journal of hepatology · 2020
    Systematic review9 studies pooledDetoxification forSAMe
  4. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
    Zhang L; Liu XH; Qi HB; Li Z; Fu XD; Chen L; Shao Y · European review for medical and pharmacological sciences · 2016
    Randomized trial120 participantsDetoxification forSAMe
  5. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis.
    Roncaglia N; Locatelli A; Arreghini A; Assi F; Cameroni I; Pezzullo JC; Ghidini A · BJOG : an international journal of obstetrics and gynaecology · 2004
    Randomized trial46 participantsDetoxification forSAMe
  6. Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
    Liu GY; Wang W; Jia WD; Xu GL; Ma JL; Ge YS; Yu JH; Sun QK; Meng FL · World journal of surgical oncology · 2014
    Non-randomized trial81 participantsDetoxification forSAMe
  7. Interventions for treating cholestasis in pregnancy.
    Burrows RF; Clavisi O; Burrows E · The Cochrane database of systematic reviews · 2002
    Systematic review227 participants9 studies pooledDetoxification forSAMe
  8. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
    Mato JM; Cámara J; Fernández de Paz J; Caballería L; Coll S; Caballero A; García-Buey L; Beltrán J; Benita V; Caballería J; Solà R; Moreno-Otero R; Barrao F; Martín-Duce A; Correa JA; Parés A; Barrao E; García-Magaz I; Puerta JL; Moreno J; Boissard G; Ortiz P; Rodés J · Journal of hepatology · 1999
    Randomized trial123 participantsDetoxification forSAMe
  9. Beneficial effects of S-adenosyl-L-methionine on post-hepatectomy residual liver function: a prospective, randomized, controlled clinical trial.
    Su ZR; Cui ZL; Ma JL; Li JS; Ge YS; Yu JH; Pan JH; Xu GL; Jia WD · Hepato-gastroenterology · 2014
    Randomized trial79 participantsDetoxification forSAMe
  10. Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease.
    Ivashkin VT; Maevskaya MV; Kobalava ZD; Uspenskiy YP; Fominih JA; Rozanov AV; Tolkacheva VV; Sotnikova TI; Alikhanov BA; Gorbacheva IA; Ershova OB; Znakhyrenko AA; Sokolov KA; Sander-Struckmeier S · Minerva gastroenterologica e dietologica · 2019
    Single-arm trial72 participantsDetoxification forSAMe
  11. Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: a randomized clinical trial.
    Asgarshirazi M; Shariat M; Sheikh M · Hepatobiliary & pancreatic diseases international : HBPD INT · 2018
    Randomized trial55 participantsDetoxification forFolate
  12. Homocysteine, folate, and nonalcoholic fatty liver disease: a systematic review with meta-analysis and Mendelian randomization investigation.
    Yuan S; Chen J; Dan L; Xie Y; Sun Y; Li X; Larsson SC · The American journal of clinical nutrition · 2022
    Meta-analysis30,368 participants22 studies pooledDetoxification forFolate
  13. Serum folate levels and urinary arsenic methylation profiles in the US population: NHANES, 2003-2012.
    Zhang X; Xu X; Zhong Y; Power MC; Taylor BD; Carrillo G · Journal of exposure science & environmental epidemiology · 2020
    Cross-sectional study11,016 participantsDetoxification forFolate
  14. Association between serum folate levels and blood concentrations of cadmium and lead in US adults.
    Wu Z; Hu H; Wang C; Wu J; Xiong Y; Fu Y; Cheng X; Su H; Li P · Environmental science and pollution research international · 2022
    Cross-sectional study15,501 participantsDetoxification forFolate
  15. Effects of Folic Acid Supplementation on Liver Enzymes, Lipid Profile, and Insulin Resistance in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial.
    Molaqanbari MR; Zarringol S; Talari HR; Taghizadeh M; Bahmani F; Mohtashamian A; Ebrahimzadeh A; Sharifi N · Advanced biomedical research · 2023
    Randomized trial66 participantsDetoxification forFolate